Hepatic steatosis is considered as a 'benign' condition closely linked to impaired insulin action and hyperglycaemia in type 2 diabetes23; thus, we are interested in the MSCs’ effects and potential molecular mechanism on NAFLD. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.